CELH
Celsius Holdings, Inc.
CELH's fundamentals are strong and it looks cheap: trading at 35x earnings, less than half its usual 142x. Analysts expect strong earnings growth, though they disagree widely on how much.
IMKTA
Ingles Markets, Incorporated
There isn't enough reported data to score IMKTA yet.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
IMKTA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Strong |
IMKTA's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
IMKTA PE Valuation
IMKTA has no meaningful PE right now: it lost money over the past year.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
IMKTA Forward outlook
There aren't enough analyst estimates for IMKTA to show an outlook.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH has the stronger earnings trend. Trailing diluted EPS is up 718% for CELH versus IMKTA down 65%.
IMKTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | $2.97 | -65% |
| Q1 2025 | $3.26 | -65% |
| Q4 2024 | $4.14 | -58% |
| Q3 2024 | $5.55 | -50% |
| Q2 2024 | $8.46 | -30% |
| Q1 2024 | $9.33 | -29% |
| Q4 2023 | $9.78 | -33% |
| Q3 2023 | $11.15 | -23% |
IMKTA's earnings per share have fallen from their peak: $2.97 over the past year, against $14.66 in early 2022.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over IMKTA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over IMKTA on profitability, with a higher operating margin.
IMKTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.4B | +1.6% |
| Q1 2026 | $1.3B | -1.8% |
| Q4 2025 | $1.4B | +6.6% |
| Q3 2025 | $1.4B | -2.1% |
| Q2 2025 | $1.3B | -3.4% |
| Q1 2025 | $1.3B | -2.6% |
| Q4 2024 | $1.3B | -13% |
| Q3 2024 | $1.4B | -12% |
IMKTA's revenue grew through 2024 and has held roughly level since: $1.4B last quarter, up 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 2.5% | -0.3 points |
| Q1 2026 | 2.6% | +1 points |
| Q4 2025 | 2.9% | +1 points |
| Q3 2025 | 2.6% | +2.7 points |
| Q2 2025 | 2.8% | -0.4 points |
| Q1 2025 | 1.6% | -1.6 points |
| Q4 2024 | 1.8% | -2.2 points |
| Q3 2024 | -0.1% | -4.6 points |
IMKTA's operating margin was 2.5% last quarter, about level with the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
IMKTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $43.6M | -3.9% |
| Q1 2026 | $67.1M | +73% |
| Q4 2025 | $2.1M | +$83.5M |
| Q3 2025 | $36.8M | +577% |
| Q2 2025 | $45.4M | -23% |
| Q1 2025 | $38.9M | +10% |
| Q4 2024 | -$81.4M | -$33.8M |
| Q3 2024 | $5.4M | -90% |
IMKTA still generates free cash flow, though less than at its 2020 peak: $150M over the past year.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over IMKTA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
IMKTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +48.6K shares |
| 1 year | +0.3% | +48.6K shares |
| 3 years | +0.3% | +48.6K shares |
| 5 years | +0.3% | +48.6K shares |
| Available history | -5.3% | -1.1M shares |
IMKTA has 19M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over IMKTA on leverage, with a lower net debt burden relative to earnings.
IMKTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.2x | Healthy |
| Q3 2024 | 0.8x | Very low |
IMKTA's net debt is less than a year of its operating earnings (EBITDA).
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
IMKTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.2 | Neutral |
| Stochastic | 28.5 | Neutral |
IMKTA's weekly RSI is 47 (neutral) and its Stochastic is 29 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
IMKTA PE vs Consumer Defensive Sector
| Metric | IMKTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 19x | — |
IMKTA has no meaningful PE right now: it lost money over the past year.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
IMKTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.1 | 1.4% below |
| 20 week MA | $85.9 | 2.4% below |
| 50 week MA | $84.5 | 0.7% below |
| 100 week MA | $75.1 | 12% above |
| 200 week MA | $77.1 | 8.8% above |
IMKTA has slipped below its 8-, 20- and 50-week averages, though it's still 8.8% above its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
IMKTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.7 | $40.7 | -15% |
| 2021 | $40.7 | $87.2 | +114% |
| 2022 | $87.2 | $99.2 | +14% |
| 2023 | $99.2 | $86.4 | -13% |
| 2024 | $86.4 | $65.3 | -24% |
| 2025 | $65.3 | $70.3 | +7.6% |
| 2026 YTD | $70.3 | $83.9 | +19% |
IMKTA has the edge over CELH on returns for 2026, with the stronger performance.